AstraZeneca Pharma India Limited has informed the Exchange regarding 'Legible copy of the un-audited financial results for the quarter ended June 30, 2025'.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has submitted a legible copy of its un-audited financial results for the quarter ended June 30, 2025 to the stock exchanges. This is a routine procedural filing, typically submitted to provide a clearer or corrected version of the results already filed earlier. The underlying financial figures are referenced but not reproduced in this particular announcement. Investors should refer to the actual results document or the company's earlier filing for the detailed numbers on revenue, expenses, profit, and segment performance.
This is a compliance/administrative filing with no direct material impact on the stock price. Shareholders should look at the original results filing for Q1 FY26 to assess actual business performance.